Sign In
Buy BAYRY
$9.92
+0.0400 (+0.405%)
At Close: Jun 03, 2026
Bayer stock jump 9% as stroke drug trial revives confidence in pipeline
05:01am, Monday, 24'th Nov 2025
Bayer shares surged on Monday after the company reported encouraging late-stage clinical trial results for its experimental cardiovascular drug asundexian, offering a rare boost for a pharmaceutical d
Bayer's stock is jumping on secondary stroke drug's trial success
04:47am, Monday, 24'th Nov 2025
Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.
Bayer shares up more than 8% on revived fortunes for blood thinner
03:35am, Monday, 24'th Nov 2025
Shares in Bayer jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key cardiovascular drug that suffered a major development setback two years ago.
Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment
02:04am, Monday, 24'th Nov 2025
The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study.
Bayer reports positive results for blood thinner after 2023 setback
11:48am, Sunday, 23'rd Nov 2025
German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising
12:53pm, Thursday, 20'th Nov 2025
The Food and Drug Administration (FDA) on Wednesday granted accelerated approval to Bayer AG‘s (OTC: BAYRY) Hyrnuo (sevabertinib) for adults with a specific type of advanced lung cancer.
Bayer Just Cracked the Lung Cancer Market--Here's Why Investors Are Paying Attention
06:42am, Thursday, 20'th Nov 2025
Bayer AG (BAYRY) just picked up a shot of momentum from the US Food and Drug Administration, which granted accelerated approval for Hyrnuo, its new treatment fo
US FDA approves Bayer's lung cancer drug
02:53pm, Wednesday, 19'th Nov 2025
The U.S. Food and Drug Administration on Wednesday approved Bayer's drug for patients with a type of lung cancer.
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
09:56am, Wednesday, 19'th Nov 2025
Bayer BAYRY obtained European Commission approval for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or caused by ad
Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term
10:41am, Friday, 14'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bayer Aktiengesellschaft (BAYRY) Q3 2025 Earnings Call Transcript
06:01pm, Wednesday, 12'th Nov 2025
Bayer Aktiengesellschaft (OTCPK:BAYRY) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jost Reinhard - Senior VP & Head of Investor Relations William Anderson - Chairman of th
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks
01:34pm, Wednesday, 12'th Nov 2025
On Wednesday, Bayer AG (OTC:BAYRY) reported adjusted earnings of 17 cents per ADS (57 cents in euros), up from 7 cents a year ago (24 cents euros).
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
01:31pm, Wednesday, 12'th Nov 2025
Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
12:00pm, Wednesday, 12'th Nov 2025
Exploring Kahn Brothers (Trades, Portfolio)' Recent 13F Filing and Investment Strategies Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing
